Prevention trial for Hiv
Official title Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
ClinicalTrials.gov ID: NCT05669534
What this study is testing
What is Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis?
This is an investigational combination of a daily pill and a behavioral support program being studied to help prevent HIV in people using opioids. The medication is designed to stop the HIV virus from infecting cells if it enters the body.
Also referred to as PrEP.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if a program that helps with memory and focus improves how people understand and use HIV prevention advice.
- Who it's for
- The study is looking for people who use opioids and have recently started taking medication for opioid use disorder and HIV prevention pills.
- What's involved
- Participants will take part in a support program designed to help them process information about staying healthy and preventing HIV.
- Time commitment
- The source text does not specify the total duration or the number of visits required.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- being 18 years or older
- meeting DSM-V criteria for opioid dependence and being newly prescribed and adherent to Medication for Opioid Use Disorder (e.g., methadone...
- showing mild cognitive impairment based on the Montreal Cognitive Assessment (MoCA) screening
- having initiated Pre-Exposure Prophylaxis (PrEP) within the past week
- confirming HIV-negative status through proof of PrEP prescription
You likely can't join if
- unable to provide consent
- actively suicidal
- actively homicidal
- actively psychotic
- display MoCA scores suggestive of dementia
See the full eligibility criteria
- being 18 years or older
- meeting DSM-V criteria for opioid dependence and being newly prescribed and adherent to Medication for Opioid Use Disorder (e.g., methadone, buprenorphine) at the APT Foundation, Inc.
- showing mild cognitive impairment based on the Montreal Cognitive Assessment (MoCA) screening
- having initiated Pre-Exposure Prophylaxis (PrEP) within the past week
- confirming HIV-negative status through proof of PrEP prescription
- reporting unsafe injection drug use practices or unprotected sex within the past 3 months
- having a cell phone
- being able to read and understand in English
- unable to provide consent
- actively suicidal
- actively homicidal
- actively psychotic
- display MoCA scores suggestive of dementia
The study team makes the final eligibility decision.
Where it is enrolling
- New Haven, Connecticut, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at New Haven, Connecticut, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.